Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Significant Growth in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,828,008 shares, an increase of 1,667.8% from the August 15th total of 103,406 shares. Approximately 1.5% of the shares of the stock are sold short. Based on an average trading volume of 8,029,553 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On Xtant Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AWM Investment Company Inc. bought a new stake in shares of Xtant Medical in the 2nd quarter valued at approximately $2,516,000. Wiregrass Investment Management LLC bought a new position in shares of Xtant Medical during the 4th quarter valued at approximately $81,000. Renaissance Technologies LLC raised its holdings in Xtant Medical by 28.8% during the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock valued at $721,000 after buying an additional 205,945 shares during the period. Vanguard Group Inc. raised its holdings in Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after buying an additional 104,159 shares during the period. Finally, Mink Brook Asset Management LLC raised its holdings in Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after buying an additional 60,997 shares during the period. 69.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Loop Capital set a $1.00 price objective on shares of Xtant Medical in a report on Wednesday, September 2nd. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Xtant Medical currently has a consensus rating of “Buy” and a consensus price target of $1.00.

Xtant Medical Price Performance

Xtant Medical stock opened at $0.33 on Friday. Xtant Medical has a 52-week low of $0.27 and a 52-week high of $0.95. The company has a quick ratio of 1.05, a current ratio of 2.16 and a debt-to-equity ratio of 0.18. The firm’s fifty day moving average is $0.39 and its 200 day moving average is $0.47. The company has a market cap of $46.46 million, a price-to-earnings ratio of -4.14 and a beta of -0.15.

Xtant Medical (NYSEAMERICAN:XTNT) last posted its earnings results on Tuesday, August 11th. The medical device company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.05). The business had revenue of $23.03 million during the quarter, compared to the consensus estimate of $24.88 million. Xtant Medical had a negative return on equity of 23.45% and a negative net margin of 10.17%.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.